Här är en ny analys av Biohit. 
Biohit issued a profit warning related to revenue, but despite this, the new 2024 earnings guidance (EBIT percentage 16-18%) clearly exceeded our expectations. Biohit’s profitability fluctuates, so we do not expect profitability to reach the very strong H2’24 level in the future. However, we raise our earnings forecasts moderately for the coming years based on the strong performance. The return/risk ratio of the stock that we already consider attractive improves another notch, so we raise our recommendation to Buy (was Accumulate) and raise the target price to EUR 2.9 (was 2.7).